Objectives China suffers from high burdens of human papillomavirus (HPV) and cervical
cancer, whereas the uptake of HPV vaccine remains low. The first Chinese domestic HPV …

Objectives Many reviews have been conducted on the economic evaluation of the HPV
vaccine in global north countries. But there is a dearth of such reviews in the Global South …

Background Coinciding with the release of the first Chinese domestic human papillomavirus
(HPV) vaccine Cecolin in 2019, and the substantial advancements in cervical cancer …

Background Human papillomavirus (HPV) vaccines have been proven effective against
cervical cancer. However, HPV vaccination is not included in the Chinese immunization …

Background China has a high prevalence of human papillomavirus (HPV) and a
consequently high burden of disease with respect to cervical cancer. The HPV vaccine has …

Background In countries with limited resources, a targeted HPV vaccination strategy by
focusing in selected regions is preferable to be implemented than a nationwide vaccination …

Abstract The World Health Organization recommends establishing that human
papillomavirus vaccination is cost-effective before vaccine introduction. We searched …

Background: Prophylactic human papilloma virus (HPV) vaccines represent a promising
option for cervical cancer (CC) prevention in countries where screening, diagnostics and …

Abstract Background The World Health Organization (WHO) recommends that the cost
effectiveness of introducing human papillomavirus (HPV) vaccination is considered before …

Objectives To evaluate the cost-effectiveness of the 9-valent human papillomavirus (HPV)
vaccine for the prevention of cervical cancer in China. Design Health economic modelling …